Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.97 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13284143 | 0.89 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL25431 | 0.88 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL28905219 | 0.87 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL1083668 | 0.87 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL41046 | 0.87 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL2860723 | 0.87 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL194412 | 0.87 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL27945061 | 0.87 | OPRM1 (0.97) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL10246305 | 0.86 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Meperidine SCHEMBL3054250 | 0.86 | OPRM1 (0.94) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149900-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149900-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | OPRM1 2013/4885OPRD1 3594/4885OPRK1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.